Acacia Pharma is preparing for filing an NDA for BAREMSIS™ for the treatments of post operative nausea & vomiting.
For further information: www.acaciapharma.com
Atox Bio is a late stage biotechnology company that develops novel immunomodulators to treat critically ill patients. Initial focus is on patients with Necrotizing Soft Tissue Infections (“flesh eating bacteria”), a rare, life threatening, infection for which no current therapy exists. AB103, the company’s lead product, is studied in ACCUTE (AB103 Clinical Composite endpoint StUdy in necrotizing soft Tissue InfEctions), a phase III clinical trial. AB103 received Orphan Drug designation from the FDA and EMA and Fast Track designation from the FDA.
For further information: www.atoxbio.com
Biom’Up is a specialist in collagen-based absorbable medical devices for biosurgery and is developing a new generation hemostatic product, HEMOBLAST TM. HEMOBLASTTM Bellows is currently being tested in a prospective, randomized, controlled, multicenter, pivotal, clinical investigation evaluating the safety and efficacy in Cardiothoracic, Abdominal, and Orthopedic Lower Extremity Surgeries.
For further information: www.biomup.com
BONESUPPORT has a platform for delivering drugs to bone using CERAMENT™. This carrier is an injectable radio opaque bone void filler that rapidly remodels into bone. Bonesupport markets and sells CERAMENT™ in EU and USA and CERAMENT™ loaded with the antibiotics Gentamicin or Vancomycin in EU.
For further information: www.bonesupport.se
Cydan Development is an orphan drug accelerator that identifies and de-risks drug candidates targeting orphan and rare diseases and form stand-alone companies and strategic partnerships around successful such candidates.
For further information: www.cydanco.com
DySIS develops and markets next generation colposcopes for early detection and diagnosis of cervical cancer. The DySIS colposcope is a high resolution digital colposcope with an adjunctive map. The DySISmap is generated by a proprietary technology that measures the aceto-whitening reaction and summarizes it in the form of an intuitive map. The DySISmap is overlaid on the live image of the cervix to help with the identification of the most relevant biopsy sites.
For further information: www.dysismedical.com
Enterome is pioneering the development of novel drugs and diagnostics to support a personalized therapeutic approach of microbiome-related diseases with a special focus on Inflammatory Bowel Disease and Immuno Oncology. Their lead program is in phase I trials.
For further information: www.enterome.com
Imara is developing novel oral treatment for patients with sickle cell disease and other haemoglobinopathies. The company is in a Phase I clinical trial with IMR687, a highly selective and potent small molecule inhibitor of phosphodiesterase-9.
For further information: www.imaratx.com
PsiOxus is developing novel therapeutics based on its platform of tumour-targeted delivery with oncolytic vaccines that can be administered systemically, and replicates in and kill cancer cells, but not normal cells.
For further information: www.psioxus.com
Biopharmaceutical company focused on the development of SNF472 – an experimental drug for the treatment of cardiovascular diseases linked to calcification in the End Stage Renal Disease (ESRD) population undergoing haemodialysis. Completed phase Ia studies in healthy volunteers and a phase Ib/IIa study in haemodialysis patients. Sanifit has started a phase II study in ESRD and extended the orphan program in calciphylaxis into a phase II/III clinical trial.
For further information: www.sanifit.com
scPharmaceuticals has a proprietary device technology that enables subcutaneous administration of parenteral drugs. The sc2Wear™ pump, serves as the platform for a pipeline of proven drugs that enables a new anytime-anywhere treatment model that is independent of a clinical setting.
For further information: www.scpharma.com
Spero has a pipeline of novel treatments for bacterial infections. The lead program is in phase I clinical trials.
For further information: www.sperotherapeutics.com
Thesan Pharmaceuticals is a biopharmaceutical company based in San Diego, US, dedicated to the development of novel therapeutics for disorders of the skin.
For further information: www.thesanpharma.com
VHsquared is a clinical stage company focused on transformational oral biologics – Vorabodies™ – for inflammatory bowel disease. Vorabodies™ are oral gut-restricted domain antibodies targeting local immuno-inflammatory targets in the GI tract. The most advanced Vorabody, is in phase II clinical trials for Crohn’s Disease.
For further information: www.vhsquared.com